menu
    • menu

    Company profile for Ocugen

    NEW Drugs in Dev: 13
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases wi...
    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OcugenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5 Great Valley Parkway, Suite 160 Malvern, PA 19355
    Telephone
    Telephone
    484.328.4701
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ocugen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ocugen
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Ocugen

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocugen Appoints Rita Johnson-Greene To Chief Financial Officer
    Ocugen Appoints Rita Johnson-Greene To Chief Financial Officer

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234410/0/en/Ocugen-Appoints-Rita-Johnson-Greene-to-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Ocugen Closes $22.5M Direct Stock Offering
    Ocugen Closes $22.5M Direct Stock Offering

    23 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/23/3224703/0/en/Ocugen-Inc-Announces-Closing-of-22-5-Million-Underwritten-Registered-Direct-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    23 Jan 2026
    Share Share
    Ocugen Prices $22.5M Common Stock Offering
    Ocugen Prices $22.5M Common Stock Offering

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222799/0/en/Ocugen-Inc-Announces-Pricing-of-22-5-Million-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Ocugen Update Charts Course For Rivalry With Apellis, Astellas
    Ocugen Update Charts Course For Rivalry With Apellis, Astellas

    15 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ocugen-posts-midphase-gene-therapy-data-charting-course-rivalry-apellis-and-astellas

    FIERCE BIOTECH
    15 Jan 2026
    Share Share
    Ocugen Reports Promising Phase 2 Results For OCU410 Gene Therapy
    Ocugen Reports Promising Phase 2 Results For OCU410 Gene Therapy

    15 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219537/0/en/Ocugen-Announces-Positive-Preliminary-Phase-2-Data-from-OCU410-Modifier-Gene-Therapy-for-Geographic-Atrophy-Secondary-to-Dry-Age-Related-Macular-Degeneration.html

    GLOBENEWSWIRE
    15 Jan 2026
    Share Share
    Ocugen Webcast On OCU410 Phase 2 Trial Data Set For January 15
    Ocugen Webcast On OCU410 Phase 2 Trial Data Set For January 15

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217627/0/en/Ocugen-to-Host-Webcast-on-Thursday-January-15-at-8-30-a-m-ET-to-Discuss-OCU410-Phase-2-Clinical-Trial-Data.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search